AIM: To investigate the expression of midkine in @entity1721 ( @entity1721 ) and analyze its relationship with clinicopathological features. METHODS: RT-PCR and immunocytochemical staining were used to detect the expression of midkine mRNA and protein in EC109 cells, respectively. Then the expression of midkine in 66 cases of @entity1721 samples were detected by immunohistochemistry using monoclonal antibodies against @entity1 midkine. RESULTS: Midkine was expressed in EC109 cell by RT-PCR and immunocytochemistry. The immunoreactivity was detected in 56.1% (37/66) of the @entity1721 samples. The expression of midkine was found in cytoplasm of @entity5 cells. Notably, the intensity of midkine was stronger at the area abundant in vessels and the invading border of the @entity5 . Midkine was more intensely expressed in well differentiated @entity5 (76.9%) than in moderately and poorly differentiated @entity5 (43.1% and 41.2%, respectively) (P<0.05). There was no statistically significant correlation between midkine expression and gender, age, clinical stage, lymph node @entity3 or survival in @entity1721 . CONCLUSION: Midkine is overexpressed in @entity1721 . It may play a role in @entity5 angiogenesis and invasion. The expression of midkine is correlated with @entity5 cell differentiation in @entity1721 . The more poorly @entity5 cells differentiate, the weaker midkine expresses.

Expression of midkine and its clinical significance in XXXX .

@entity1 :: ('9606', 'Species') :: ['human'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors'] @entity1721 :: ('MESH:C562729', 'Disease') :: ['esophageal squamous cell carcinoma', 'ESCC'] @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']
@entity1721 :: (MESH:C562729,Disease) :: ['esophageal squamous cell carcinoma']
